July 30, 2008 08:00 AM Eastern Time

BUSINESS WIRE

Noven Announces Final FDA Approval of Stavzor(TM) for the Treatment of Bipolar Disorder, Seizures and Migraine Headaches

Stavzor(TM) (valproic acid delayed release capsules) (Photo: Business Wire)

Stavzor(TM) (valproic acid delayed release capsules) (Photo: Business Wire)

Opens in new window

Download

Thumbnail JPEG, 27x72, 1.7 KB
Preview JPEG, 54x144, 3.4 KB
Small JPEG, 113x300, 8.9 KB
Full Size JPEG, 2472x6512, 1.0 MB

Smart Multimedia Gallery

Stavzor(TM) (valproic acid delayed release capsules) (Photo: Business Wire)

Stavzor(TM) (valproic acid delayed release capsules) (Photo: Business Wire)

http://www.businesswire.com/multimedia/home/20080730005608/en/1659279/Noven-Announces-Final-FDA-Approval-Stavzor-TM

View and Share Logo

http://www.businesswire.com/multimedia/home/20080730005608/en/1659280/Noven-Announces-Final-FDA-Approval-Stavzor-TM

View and Share Logo

Share

Email

All News | News with Multimedia > News Release: Noven Announces Final FDA Approval of Stavzor(T...